Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-11-01

Clinical Trial Update: Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating vandetanib's effect on cellular markers in invasive breast cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vandetanib (vandetanib)

Snippet

Sponsor: Ronald Weigel | Conditions: Invasive Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-11-01